The Experts below are selected from a list of 4974 Experts worldwide ranked by ideXlab platform

Miccheli A. - One of the best experts on this subject based on the ideXlab platform.

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study. Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

Calvani R. - One of the best experts on this subject based on the ideXlab platform.

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study. Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • Circulating Mitochondrial-Derived Vesicles, Inflammatory Biomarkers and Amino Acids in Older Adults With Physical Frailty and Sarcopenia: A Preliminary BIOSPHERE Multi-Marker Study Using Sequential and Orthogonalized Covariance Selection – Linear Discriminant Analysis
    'Frontiers Media SA', 2020
    Co-Authors: Marzetti E., Calvani R., Marini F., Biancolillo A., Gervasoni J., Primiano A., Guerra F., Coelho-junior H. J., Landi F., Bernabei R.
    Abstract:

    Physical frailty and sarcopenia (PF&S) is a prototypical Geriatric Condition characterized by reduced physical function and low muscle mass. The multifaceted pathophysiology of this Condition recapitulates all hallmarks of aging making the identification of specific biomarkers challenging. In the present study, we explored the relationship among three processes that are thought to be involved in PF&S (i.e., systemic inflammation, amino acid dysmetabolism, and mitochondrial dysfunction). We took advantage of the well-characterized cohort of older adults recruited in the \u201cBIOmarkers associated with Sarcopenia and Physical frailty in EldeRly pErsons\u201d (BIOSPHERE) study to preliminarily combine in a multi-platform analytical approach inflammatory biomolecules, amino acids and derivatives, and mitochondrial-derived vesicle (MDV) cargo molecules to evaluate their performance as possible biomarkers for PF&S. Eleven older adults aged 70 years and older with PF&S and 10 non-sarcopenic non-frail controls were included in the analysis based on the availability of the three categories of biomolecules. A sequential and orthogonalized covariance selection\u2014linear discriminant analysis (SO-CovSel\u2013LDA) approach was used for biomarkers selection. Of the 75 analytes assayed, 16 had concentrations below the detection limit. Within the remaining 59 biomolecules, So-CovSel\u2013LDA selected a set comprising two amino acids (phosphoethanolamine and tryptophan), two cytokines (interleukin 1 receptor antagonist and macrophage inflammatory protein 1\u3b2), and MDV-derived nicotinamide adenine dinucleotide reduced form:ubiquinone oxidoreductase subunit S3 as the best predictors for discriminating older people with and without PF&S. The evaluation of these biomarkers in larger cohorts and their changes over time or in response to interventions may unveil specific pathogenetic pathways of PF&S and identify new biological targets for drug development

Stefano Volpato - One of the best experts on this subject based on the ideXlab platform.

  • muscle dysfunction in type 2 diabetes a major threat to patient s mobility and independence
    Acta Diabetologica, 2016
    Co-Authors: Lara Bianchi, Stefano Volpato
    Abstract:

    Type 2 diabetes, a common metabolic disease in older people, is a major risk factor for functional limitation, impaired mobility, and loss of independence. In older people, the pathogenesis of functional limitation and disability is complex and multifactorial. A number of potential pathways are involved including cardiovascular disease, peripheral neuropathy, overweight, osteoarthritis, visual deficit, and cognitive impairment, Conditions that are all more prevalent among patients with diabetes. Sarcopenia, a Geriatric Condition characterized by a progressive and generalized loss of skeletal muscle mass and strength, is also involved in the pathogenesis of functional limitations and disability. Recent research has shown that older patients with type 2 diabetes are often affected by skeletal muscle impairment, leading to reduced muscle strength and physical function. Insulin resistance, hyperglycemia, muscle fat infiltration, and peripheral neuropathies are hypothesized as the fundamental biological mechanisms leading to muscle impairment in people with diabetes. This review summarizes the current literature on the biological pathways responsible for skeletal muscle dysfunction in type 2 diabetes and analyzes the role of decline in muscle strength and quality on the association between diabetes and mobility disability.

Marini F. - One of the best experts on this subject based on the ideXlab platform.

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study. Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • Circulating Mitochondrial-Derived Vesicles, Inflammatory Biomarkers and Amino Acids in Older Adults With Physical Frailty and Sarcopenia: A Preliminary BIOSPHERE Multi-Marker Study Using Sequential and Orthogonalized Covariance Selection – Linear Discriminant Analysis
    'Frontiers Media SA', 2020
    Co-Authors: Marzetti E., Calvani R., Marini F., Biancolillo A., Gervasoni J., Primiano A., Guerra F., Coelho-junior H. J., Landi F., Bernabei R.
    Abstract:

    Physical frailty and sarcopenia (PF&S) is a prototypical Geriatric Condition characterized by reduced physical function and low muscle mass. The multifaceted pathophysiology of this Condition recapitulates all hallmarks of aging making the identification of specific biomarkers challenging. In the present study, we explored the relationship among three processes that are thought to be involved in PF&S (i.e., systemic inflammation, amino acid dysmetabolism, and mitochondrial dysfunction). We took advantage of the well-characterized cohort of older adults recruited in the \u201cBIOmarkers associated with Sarcopenia and Physical frailty in EldeRly pErsons\u201d (BIOSPHERE) study to preliminarily combine in a multi-platform analytical approach inflammatory biomolecules, amino acids and derivatives, and mitochondrial-derived vesicle (MDV) cargo molecules to evaluate their performance as possible biomarkers for PF&S. Eleven older adults aged 70 years and older with PF&S and 10 non-sarcopenic non-frail controls were included in the analysis based on the availability of the three categories of biomolecules. A sequential and orthogonalized covariance selection\u2014linear discriminant analysis (SO-CovSel\u2013LDA) approach was used for biomarkers selection. Of the 75 analytes assayed, 16 had concentrations below the detection limit. Within the remaining 59 biomolecules, So-CovSel\u2013LDA selected a set comprising two amino acids (phosphoethanolamine and tryptophan), two cytokines (interleukin 1 receptor antagonist and macrophage inflammatory protein 1\u3b2), and MDV-derived nicotinamide adenine dinucleotide reduced form:ubiquinone oxidoreductase subunit S3 as the best predictors for discriminating older people with and without PF&S. The evaluation of these biomarkers in larger cohorts and their changes over time or in response to interventions may unveil specific pathogenetic pathways of PF&S and identify new biological targets for drug development

Primiano A. - One of the best experts on this subject based on the ideXlab platform.

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study: Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the \u201cMetabolic biomarkers of frailty in older people with type 2 diabetes mellitus\u201d (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • The “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study. Rationale, design and methods
    'Elsevier BV', 2020
    Co-Authors: Calvani R., Rodriguez-manas L., Picca A., Marini F., Biancolillo A., Laosa O., Pedraza L., Gervasoni J., Primiano A., Miccheli A.
    Abstract:

    Type 2 diabetes mellitus (T2DM) is a leading cause of disability globally. Frailty is a high-impact Geriatric Condition that increases the risk of negative health outcomes and imposes remarkable health and social burden. Both frailty and T2DM show multifaceted pathophysiology, phenotypic heterogeneity, and fluctuating manifestations that challenge their management, especially when the two Conditions co-occur. Muscle wasting and its correlates (e.g., metabolic perturbations and functional decline) that underlie frailty may exacerbates clinical manifestations of T2DM in older people, resulting in worse prognosis. The intrinsic complexity of frailty and T2DM has hampered the identification of clinically meaningful biomarkers to track the clinical progression of the two Conditions over time and to monitor the efficacy of pharmacological and lifestyle interventions. Here, we propose an innovative approach for biomarker identification that couples multi-platform analytical determinations with chemometric modeling strategies. This novel multi-marker discovery process is described in the context of the “Metabolic biomarkers of frailty in older people with type 2 diabetes mellitus” (MetaboFrail) study that aimed at identifying metabolic biomarkers of frailty in functionally limited older persons with T2DM

  • Circulating Mitochondrial-Derived Vesicles, Inflammatory Biomarkers and Amino Acids in Older Adults With Physical Frailty and Sarcopenia: A Preliminary BIOSPHERE Multi-Marker Study Using Sequential and Orthogonalized Covariance Selection – Linear Discriminant Analysis
    'Frontiers Media SA', 2020
    Co-Authors: Marzetti E., Calvani R., Marini F., Biancolillo A., Gervasoni J., Primiano A., Guerra F., Coelho-junior H. J., Landi F., Bernabei R.
    Abstract:

    Physical frailty and sarcopenia (PF&S) is a prototypical Geriatric Condition characterized by reduced physical function and low muscle mass. The multifaceted pathophysiology of this Condition recapitulates all hallmarks of aging making the identification of specific biomarkers challenging. In the present study, we explored the relationship among three processes that are thought to be involved in PF&S (i.e., systemic inflammation, amino acid dysmetabolism, and mitochondrial dysfunction). We took advantage of the well-characterized cohort of older adults recruited in the \u201cBIOmarkers associated with Sarcopenia and Physical frailty in EldeRly pErsons\u201d (BIOSPHERE) study to preliminarily combine in a multi-platform analytical approach inflammatory biomolecules, amino acids and derivatives, and mitochondrial-derived vesicle (MDV) cargo molecules to evaluate their performance as possible biomarkers for PF&S. Eleven older adults aged 70 years and older with PF&S and 10 non-sarcopenic non-frail controls were included in the analysis based on the availability of the three categories of biomolecules. A sequential and orthogonalized covariance selection\u2014linear discriminant analysis (SO-CovSel\u2013LDA) approach was used for biomarkers selection. Of the 75 analytes assayed, 16 had concentrations below the detection limit. Within the remaining 59 biomolecules, So-CovSel\u2013LDA selected a set comprising two amino acids (phosphoethanolamine and tryptophan), two cytokines (interleukin 1 receptor antagonist and macrophage inflammatory protein 1\u3b2), and MDV-derived nicotinamide adenine dinucleotide reduced form:ubiquinone oxidoreductase subunit S3 as the best predictors for discriminating older people with and without PF&S. The evaluation of these biomarkers in larger cohorts and their changes over time or in response to interventions may unveil specific pathogenetic pathways of PF&S and identify new biological targets for drug development